Uncovering the Mechanisms of Cryptotanshinone as a Therapeutic Agent Against Hepatocellular Carcinoma

被引:18
|
作者
Luo, Yi [1 ,2 ]
Song, Lei [1 ,2 ]
Wang, Xinyu [3 ]
Huang, Yujie [1 ,2 ]
Liu, Yongqiang [1 ,2 ]
Wang, Qi [1 ,2 ]
Hong, Ming [1 ,2 ]
Yuan, Zhongyu [3 ]
机构
[1] Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Guangzhou, Peoples R China
[2] Guangzhou Univ Chinese Med, Inst Clin Pharmacol, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China
关键词
hepatocellular carcinoma; cryptotanshinone; system pharmacology; apoptosis; autophagy; PI3K/AKT/MTOR PATHWAY; SYSTEMS PHARMACOLOGY; NATURAL-PRODUCTS; CELL-DEATH; IN-VIVO; CANCER; APOPTOSIS; AUTOPHAGY; INHIBITION; TARGET;
D O I
10.3389/fphar.2020.01264
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatocellular carcinoma (HCC) is a fatal and dominant form of liver cancer that currently has no effective treatment or positive prognosis. In this study, we explored the antitumor effects of cryptotanshinone (CPT) against HCC and the molecular mechanisms underlying these effects using a systems pharmacology and experimental validation approach. First, we identified a total of 296 CPT targets, 239 of which were also HCC-related targets. We elucidated the mechanisms by which CPT affects HCC through multiple network analysis, including CPT-target network analysis, protein-protein interaction network analysis, target-function network analysis, and pathway enrichment analysis. In addition, we found that CPT induced apoptosis in Huh7 and MHCC97-H ells due to increased levels of cleaved PARP, Bax, and cleaved caspase-3 and decreased Bcl-2 expression. CPT also induced autophagy in HCC cells by increasing LC3-II conversion and the expression of Beclin1 and ATG5, while decreasing the expression of p62/SQSTM1. Autophagy inhibitors (3-methyladenine and chloroquine) enhanced CPT-induced proliferation and apoptosis, suggesting that CPT-induced autophagy may protect HCC cells against cell death. Furthermore, CPT was found to inhibit the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway. Interestingly, activation of PI3K by insulin-like growth factor-I inhibited CPT-induced apoptosis and autophagy, suggesting that the PI3K/AKT/mTOR signaling pathway is involved in both CPT-induced apoptosis and autophagy. Finally, CPT was found to inhibit the growth of Huh7 xenograft tumors. In conclusion, we first demonstrated the antitumor effects of CPT in Huh7 and MHCC97-H cells, bothin vitroandin vivo. We elucidated the potential antitumor mechanism of CPT, which involved inducing apoptosis and autophagy by inhibiting the PI3K/Akt/mTOR signaling pathway. Our findings may provide valuable insights into the clinical application of CPT, serving as a potential candidate therapeutic agent for HCC treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] In vitro and vivo anti-tumor activity and mechanisms of the new cryptotanshinone derivative 11 against hepatocellular carcinoma
    Yang, Xinni
    She, Xianlan
    Zhao, Zhishuang
    Ren, Jian
    Wang, Peiying
    Dong, Haoqi
    Zhao, Qin-shi
    Liu, Jiangxin
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 971
  • [2] Uncovering the anti-metastasis effects and mechanisms of capsaicin against hepatocellular carcinoma cells by metabolomics
    Wang, Ke-xin
    Fang, Jian-song
    Qin, Xue-mei
    Du, Guan-hua
    Gao, Li
    [J]. JOURNAL OF FUNCTIONAL FOODS, 2019, 60
  • [3] Thiostrepton as a Potential Therapeutic Agent for Hepatocellular Carcinoma
    Su, Guifeng
    Yang, Qianqing
    Zhou, Heyang
    Huang, Ying
    Nie, Shiyun
    Wang, Dan
    Ma, Guangchao
    Zhang, Shaohua
    Kong, Lingmei
    Zou, Chenggang
    Li, Yan
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (17)
  • [4] Uncovering the Mechanisms of Active Components from Toad Venom against Hepatocellular Carcinoma Using Untargeted Metabolomics
    Liang, Pan
    Ma, Yining
    Yang, Luyin
    Mao, Linshen
    Sun, Qin
    Sun, Changzhen
    Liu, Zengjin
    Mazhar, Maryam
    Yang, Sijin
    Ren, Wei
    [J]. MOLECULES, 2022, 27 (22):
  • [5] Pharmacological mechanisms of norcantharidin against hepatocellular carcinoma
    Qian, Zhong-Ming
    Chen, Yun-Jin
    Bao, Yu-Xin
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (11): : 5024 - 5038
  • [6] Dedifferentiation of hepatocellular carcinoma: molecular mechanisms and therapeutic implications
    Chao, Jiashuo
    Zhao, Senlin
    Sun, Hongcheng
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (05): : 2099 - 2109
  • [7] The extracellular matrix in hepatocellular carcinoma Mechanisms and therapeutic vulnerability
    Roy, Arya Mariam
    Iyer, Renuka
    Chakraborty, Sayan
    [J]. CELL REPORTS MEDICINE, 2023, 4 (09)
  • [8] A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma
    Zhong, Lei
    Fu, Xiao-Yu
    Zou, Chan
    Yang, Ling-Ling
    Zhou, Shu
    Yang, Jiao
    Tang, Yun
    Cheng, Chuan
    Li, Lin-Li
    Xiang, Rong
    Chen, Li-Juan
    Chen, Yu-Zong
    Wei, Yu-Quan
    Yang, Sheng-Yong
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (12) : 2972 - 2983
  • [9] Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma
    Yarchoan, Mark
    Agarwal, Parul
    Villanueva, Augusto
    Rao, Shuyun
    Dawson, Laura A.
    Llovet, Josep M.
    Finn, Richard S.
    Groopman, John D.
    El-Serag, Hashem B.
    Monga, Satdarshan P.
    Wang, Xin Wei
    Karin, Michael
    Schwartz, Robert E.
    Tanabe, Kenneth K.
    Roberts, Lewis R.
    Gunaratne, Preethi H.
    Tsung, Allan
    Brown, Kimberly A.
    Lawrence, Theodore S.
    Salem, Riad
    Singal, Amit G.
    Kim, Amy K.
    Rabiee, Atoosa
    Resar, Linda
    Hoshida, Yujin
    He, Aiwu Ruth
    Ghoshal, Kalpana
    Ryan, Patrick B.
    Jaffee, Elizabeth M.
    Guha, Chandan
    Mishra, Lopa
    Coleman, C. Norman
    Ahmed, Mansoor M.
    [J]. CANCER RESEARCH, 2019, 79 (17) : 4326 - 4330
  • [10] Chemopreventive mechanisms of galangin against hepatocellular carcinoma: A review
    Fang, Dengyang
    Xiong, Zuming
    Xu, Jinming
    Yin, Jun
    Luo, Runlan
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2019, 109 : 2054 - 2061